Skip to content
Catalyst Biosciences
Primary Menu
About
Overview
Management Team
Board of Directors
Strategic Partners
Pipeline
Overview
Hemostasis
Complement
Expanded Access Policy
Science
Overview
Publications
Clinical Trials
Overview
MAA-304
MAA-202
CB 4332
Investors
Press Releases
Events and Presentations
Events
Presentations
Scientific Presentations and Publications
Financials & Filings
Stock Information
Stock Quote
Stock Chart
Corporate Governance
Leadership Team
Board of Directors
Committee Composition
Investor FAQ
Careers
Career Opportunities
Benefits
Values
Contact
Discovery and Planned Optimization of a Complement Factor C3-Inactivating Alterase, CB-2782
Post navigation
Previous:
Pharmacokinetics and Pharmacodynamics of daily Subcutaneously Administered CB2679D/ISU304 in Hemophilia B Dogs
Next:
Phase 1/2 Trial of Single and Multiple Dose Subcutaneously Administered Factor IX Variant Cb2679d/ISU304: Pharmacokinetics and Safety
X
Previous
Next
